Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes
Ding Q, Spatz E, Bena J, Morrison S, Levay M, Lin H, Grey M, Edwards N, Isaacs D, West L, Combs P, Albert N. Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes. Journal Of The American Heart Association 2023, 12: e029058. PMID: 37655510, PMCID: PMC10547320, DOI: 10.1161/jaha.122.029058.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiovascular DiseasesDiabetes Mellitus, Type 2HumansPersonal SatisfactionPropensity ScoreQuality of LifeSodium-Glucose Transporter 2 InhibitorsConceptsSodium-glucose cotransporter 2 inhibitorsGeneral health statusCardiovascular disease typesType 2 diabetesTreatment satisfactionDiabetes-specific qualityCardiovascular diseaseHealth statusDisease typeProspective observational study designPatient-reported health statusInverse probabilityNoninsulin antidiabetic medicationsSGLT-2i useSGLT-2i usersTreatment-weighted analysisCotransporter 2 inhibitorsSGLT-2 inhibitorsDiabetes treatment satisfactionObservational study designGreater reductionAntidiabetic medicationsDiabetes medicationsSecondary outcomesSymptom burden